• About us
  • Privacy Policy
  • Contact us
Neo Science Hub
ADVERTISEMENT
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
        • Dr. G. V. Purnachand
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In
No Result
View All Result
Neo Science Hub
No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Study Reveals Higher Adverse Outcomes for India-Made Generic Drugs Compared to U.S. Equivalents

Raja Aditya by Raja Aditya
2 years ago
in Healthcare & Medicine, Science News
0
Generic drugs

Study Reveals Higher Adverse Outcomes for India-Made Generic Drugs Compared to U.S. Equivalents | Neo Science Hub

A recent study published in the journal Production and Operations Management has raised significant concerns regarding the safety and quality of generic drugs produced in India. The research indicates that these drugs are associated with 54% more severe adverse events, including hospitalization and potentially fatal outcomes, than their counterparts manufactured in the United States.

Key Findings

The study’s findings were primarily based on a comparison of 2,443 generic drugs, noting that a staggering 93% of generics from emerging economies are produced in India. The researchers highlighted that the increase in adverse events was predominantly linked to “mature generic drugs,” which are those that have been in the market for an extended period. These drugs often have lower prices as their patents expire, leading to intense competition that may compromise quality.

Comparative Analysis of Drug Safety

According to the study, the adverse effects linked to Indian-manufactured generics were analyzed against reports from U.S.-made generics. The researchers noted that the substantial differences in drug manufacturing regulations and quality assurance practices between India and the U.S. contribute to this discrepancy in safety outcomes.

John Gray, a co-author of the study and professor at The Ohio State University’s Fisher College of Business, emphasized that not all generic drugs are created equal. He stated, “Where generic drugs are manufactured can make a significant difference,” pointing to the stark differences in regulatory environments that influence drug quality.

Implications for Patients and Healthcare Providers

These findings have critical implications for patients who rely on generic medications, often considered more affordable alternatives to brand-name drugs. Patients and healthcare providers may need to reconsider their choices and take into account the potential risks linked with certain generic medications, particularly those produced in countries with less stringent manufacturing regulations.

Regulatory Perspectives

The study also signals a warning to regulatory bodies like the U.S. Food and Drug Administration (FDA), which oversees drug safety and efficacy. Adverse event reporting is a fundamental part of ensuring drug safety, and the data from the FDA’s Adverse Event Reporting System (FAERS) serves as a crucial tool in monitoring the safety of medications post-approval.

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Share on WhatsApp (Opens in new window) WhatsApp
  • Share on Tumblr (Opens in new window) Tumblr
  • Share on Telegram (Opens in new window) Telegram
  • Email a link to a friend (Opens in new window) Email
Tags: Adverse OutcomesDrug SafetyfeaturedGeneric DrugsHealthcare Providerssciencenews
Raja Aditya

Raja Aditya

Associate Editor for Neo Science Hub Magazine

Other Posts

Dilemma of a Country With More Hands Than Jobs

Humanoid Robots and India: The Dilemma of a Country With More Hands Than Jobs

November 22, 2026
0
If Machines Do the Work, What Is Left for Us?

If Machines Do the Work, What Is Left for Us?

November 22, 2026
0

When the Last Antibiotic Fails: ICMR Finds 91 Per Cent Carbapenem Resistance in a Common Hospital Pathogen

Akvan Turns North and Drops a Category: IMD Now Expects a Severe Cyclone Between Narsapur and Puri, While Andhra’s Own Forecasters Expect Less

Antalya’s Last Forty-Eight Hours: Two Contradictory Paragraphs on Fossil Fuels, and India’s Line on the Carbon Budget

Disarm, Don’t Kill: CCMB Scientists Find Two Compounds That Stop a Deadly Fungus Turning Invasive

Eighty Per Cent of the Cost: Andhra Pradesh Raises the Stakes in India’s Chip-Subsidy Contest

Before the First Breath: UNEP and WHO Say Hormone-Disrupting Chemicals Reach Us in the Womb

Next Post
Black Holes

Discovering Black Holes: A Milestone Achieved by Indian-Origin Astrophysicist

Subscribe to Us

Latest Articles

Cross-section of a human eye with the optic nerve head highlighted

FDA Orders Eye-Risk Warnings on All GLP-1 Drugs, From Ozempic to Mounjaro

November 12, 2026
11

Delhi’s Diwali, Measured: Firecrackers Drove 71% of Fine Particles, Lead Hit 20 Times the Limit, and the Worst Readings Went Missing

Global Carbon Budget 2026: The World’s Fossil Emissions Dip, India’s Rise 4.4%, and the 1.5 °C Budget Is Nearly Spent

A New Kind of Blood Thinner: FDA Approves Asundexian to Prevent Repeat Strokes

Andhra Pradesh Opens the Door to Small Nuclear Reactors, Robots and Giga-Scale AI Data Centres — With the Details Still to Come

“Off the Charts”: WMO Tells COP31 That 2026 Is Among the Hottest Years on Record as a Record El Niño Builds

  • Advertise
  • Terms and Conditions
  • Privacy Policy
  • Refund Policy
  • Contact
For Feedback : Email Us

Copyrights © 2025 Neo Science Hub

No Result
View All Result
  • Home
  • e-Mag Archives
  • e-Learning
  • Categories
    • Healthcare & Medicine
    • Pharmaceutical & Chemical
    • Automobiles
    • Blogs
      • Anil Trigunayat
      • BOOKmarked
      • Chadha’s Corner
      • Cyber Gyan
      • Raul Over
      • Taste of Tradition
      • Vantage
    • Business Hub
    • Engineering
    • Innovations
    • Life Sciences
    • Space Technology
  • PhotoSynthesis
  • Subscribe Now
  • Contact us
  • Log In

Copyrights © 2025 Neo Science Hub

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist